R&D wins beyond cystic fibrosis, with the povetacicept FDA decision coming for IgA nephropathy. Click for this VRTX update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results